J. Sieper

3.1k total citations
84 papers, 2.3k citations indexed

About

J. Sieper is a scholar working on Rheumatology, Immunology and Orthopedics and Sports Medicine. According to data from OpenAlex, J. Sieper has authored 84 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Rheumatology, 24 papers in Immunology and 12 papers in Orthopedics and Sports Medicine. Recurrent topics in J. Sieper's work include Rheumatoid Arthritis Research and Therapies (60 papers), Spondyloarthritis Studies and Treatments (57 papers) and Psoriasis: Treatment and Pathogenesis (17 papers). J. Sieper is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (60 papers), Spondyloarthritis Studies and Treatments (57 papers) and Psoriasis: Treatment and Pathogenesis (17 papers). J. Sieper collaborates with scholars based in Germany, United States and Canada. J. Sieper's co-authors include Anna Katharina Simon, Eva Seipelt, Jürgen Braun, Jürgen Braun, Hildrun Haibel, M. Bollow, J. Brandt, W. Golder, J. González and Wolfgang Thriene and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Annals of the Rheumatic Diseases and Osteoporosis International.

In The Last Decade

J. Sieper

78 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Sieper Germany	18	1.7k	897	611	223	199	84	2.3k
Elisabeth Märker‐Hermann Germany	25	2.0k 1.2×	1.6k 1.8×	661 1.1×	259 1.2×	255 1.3×	95	2.9k
U. Eggens Germany	17	2.2k 1.3×	1.0k 1.1×	634 1.0×	297 1.3×	221 1.1×	28	2.7k
H. Sörensen Germany	17	2.4k 1.4×	1.1k 1.2×	948 1.6×	140 0.6×	143 0.7×	25	2.9k
Naoto Tamura Japan	23	1.0k 0.6×	884 1.0×	219 0.4×	34 0.2×	327 1.6×	196	2.2k
B.A.C. Dijkmans Netherlands	20	758 0.5×	324 0.4×	198 0.3×	64 0.3×	88 0.4×	45	1.5k
Max Hamburger United States	15	504 0.3×	501 0.6×	211 0.3×	39 0.2×	189 0.9×	26	1.4k
Barry L. Myones United States	21	568 0.3×	917 1.0×	445 0.7×	16 0.1×	268 1.3×	43	2.0k
R. Saario Finland	15	594 0.4×	320 0.4×	204 0.3×	24 0.1×	164 0.8×	25	1.1k
Raquel Cuchacovich United States	15	630 0.4×	550 0.6×	306 0.5×	25 0.1×	66 0.3×	29	1.0k
C. J. Elson United Kingdom	26	361 0.2×	576 0.6×	279 0.5×	21 0.1×	380 1.9×	68	2.0k

Countries citing papers authored by J. Sieper

Since Specialization

Citations

This map shows the geographic impact of J. Sieper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Sieper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Sieper more than expected).

Fields of papers citing papers by J. Sieper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Sieper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Sieper. The network helps show where J. Sieper may publish in the future.

Co-authorship network of co-authors of J. Sieper

This figure shows the co-authorship network connecting the top 25 collaborators of J. Sieper. A scholar is included among the top collaborators of J. Sieper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Sieper. J. Sieper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baraliakos, Xenofon, Mikhail Protopopov, Valeria Ríos Rodríguez, et al.. (2025). Radiographic structural damage in axial spondyloarthritis: is there a preferred way to quantify progression over time? Comparison of blinded versus unblinded mSASSS scoring. Annals of the Rheumatic Diseases. 84(8). 1335–1341.

Baraliakos, Xenofon, J. Sieper, Robert D. Inman, et al.. (2024). Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study. Arthritis Research & Therapy. 26(1). 197–197. 2 indexed citations

Braun, Jürgen, J. Sieper, Robert Landewé, et al.. (2017). Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies. Data Archiving and Networked Services (DANS). 69.

Heijde, D. van der, Maxime Dougados, Walter P. Maksymowych, et al.. (2016). LONG-TERM EFFICACY AND TOLERABILITY OF GOLIMUMAB IN ACTIVE NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS : RESULTS OF THE OPEN-LABEL EXTENSION OF A RANDOMIZED, DOUBLE-BLIND STUDY. Clinical and Experimental Rheumatology. 34(4). 752–752. 1 indexed citations

Rosenbaum, J. T., Martín Rudwaleit, Robert Landewé, et al.. (2014). Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis.. Data Archiving and Networked Services (DANS). 66. 1 indexed citations

Sieper, J., Martín Rudwaleit, Désirée van der Heijde, et al.. (2014). LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: 96-WEEK OUTCOMES OF THE RAPID-AXSPA TRIAL. Clinical and Experimental Rheumatology. 32(5). 785–786. 1 indexed citations

Maksymowych, Walter P., R. Landewé, Martín Rudwaleit, et al.. (2014). Effect of Certolizumab Pegol Over 48 Weeks in Patients with Axial Spondyloarthritis, including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis. The Journal of Rheumatology. 41(7). 1496–1497. 3 indexed citations

Heijde, Désirée van der, et al.. (2014). CLINICAL RESPONSE AND REMISSION IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AFTER THREE YEARS OF ADALIMUMAB THERAPY. Clinical and Experimental Rheumatology. 32(5). 829–829. 2 indexed citations

Sieper, J., Désirée van der Heijde, Maxime Dougados, et al.. (2013). SUSTAINED EFFICACY OF ADALIMUMAB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH POSITIVE MRI OF THE SACROILIAC JOINTS OR SPINE OR ELEVATED C-REACTIVE PROTEIN AT BASELINE. Lara D. Veeken. 52. 52–53. 1 indexed citations

10.

Dougados, Maxime, D. van der Heijde, J. Sieper, et al.. (2013). Safety and Efficacy Of Etanercept In Early Non-Radiographic Axial Spondyloarthritis : A Randomized, Double-Blind, Placebo-Controlled Trial At 24 Weeks. Data Archiving and Networked Services (DANS). 65. 3 indexed citations

11.

Heijde, Désirée van der, et al.. (2012). Concurrent sacroiliac joint and spinal inflammation on Mri in patients with non-radiographic axial spondyloarthritis. Clinical and Experimental Rheumatology. 30(4). 628–628. 1 indexed citations

12.

Sieper, J., et al.. (2012). DISEASE BURDEN IS COMPARABLE IN NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS AND ANKLOYSING SPONDYLITIS PATIENTS : TREATMENT IMPLICATIONS. Clinical and Experimental Rheumatology. 30(4). 638–639. 1 indexed citations

13.

Baraliakos, Xenofon, Jerry Braun, Didier Laurent, et al.. (2012). Long Term Inhibition of Interleukin (IL)-17A with Secukinumab Improves Clinical Symptoms and Reduces Spinal Inflammation As Assessed by Magnetic Resonance Imaging in Patients with Ankylosing Spondylitis.. Data Archiving and Networked Services (DANS). 64(10). 4 indexed citations

14.

Bek, Stephan, Arndt Brachat, J. Sieper, et al.. (2012). Improvement in Signs and Symptoms of Active Ankylosing Spondylitis Following Treatment with Anti-Interleukin (IL)-17A Monoclonal Antibody Secukinumab Are Paralleled by Reductions in Acute Phase Markers and Inflammatory Markers S100A8 and A9 (Calgranulin A and B). Data Archiving and Networked Services (DANS). 64(10). 2 indexed citations

15.

Landewé, Robert, Martín Rudwaleit, Désirée van der Heijde, et al.. (2012). Effect of Certolizumab Pegol On Signs and Symptoms of Ankylosing Spondyltitis and Non-Radiographic Axial Spondyloarthritis : 24 Week Results of a Double Blind Randomized Placebo-Controlled Phase 3 Axial Spondyloarthritis Study. Data Archiving and Networked Services (DANS). 64(10). 10 indexed citations

16.

Sieper, J., et al.. (2011). Efficacy and Safety of Adalimumab in Patients with Non-Radiographic Axial Spondyloarthritis - Results From a Phase 3 Study. Data Archiving and Networked Services (DANS). 63(10). 6 indexed citations

17.

Baraliakos, Xenofon, Jerry Braun, Didier Laurent, et al.. (2011). Interleukin-17A Blockade with Secukinumab Reduces Spinal Inflammation in Patients with Ankylosing Spondylitis As Early As Week 6, As Detected by Magnetic Resonance Imaging. Data Archiving and Networked Services (DANS). 63(10). 12 indexed citations

18.

Hermann, Kay‐Geert, Xenofon Baraliakos, Désirée van der Heijde, et al.. (2010). Description of spinal MRI lesions and definition of a positive MRI of the spine in axial SpA. Annals of the Rheumatic Diseases. 69(3). 3 indexed citations

19.

Heijde, Désirée van der, Ben A. C. Dijkmans, A. Kivitz, et al.. (2008). Maintenance of reduction in disease activity and partial remission in patients with Ankylosing spondylitis (AS) - 3-year results from the adalimumab (HUMIRO) trial evaluating long-term efficacy and safety in AS (ATLAS). Oxford University Research Archive (ORA) (University of Oxford). 58. 2 indexed citations

20.

Braun, Joseph M. & J. Sieper. (2001). Die glukokortikoidinduzierte Osteoporose. Der Orthopäde. 30(7). 444–450. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact